EVGN earnings: next report 2026-08-26, real EPS beat/miss history, analyst consensus Buy, P/E -0.40. Updated 2026-07-23.
Evogene (EVGN) Research Hub
Evogene (EVGN) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.4801 USD (-4.36%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.40, market cap 0.00B. This hub links to the full technical, earnings and options research available for EVGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 0.4801 USD (-4.36%) |
| 52-week range | 0.37 USD – 0.72 USD |
| Trend regime | Range |
| 14-day RSI | 37.1 (Bearish) |
| Trailing P/E | -0.40 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-26 |
Available research for EVGN
Covered Call on EVGN: how it works, illustrative setup around the real 0.4801 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EVGN: how it works, illustrative setup around the real 0.4801 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EVGN: how it works, illustrative setup around the real 0.4801 USD price, max profit/loss, breakeven and when to use it. Educational.
EVGN technical analysis: range, last 0.4801 USD, RSI 37.1, 52w range 0.37 USD–0.72 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EVGN in?
Evogene (EVGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is EVGN in an uptrend or downtrend?
As of 2026-09-11, EVGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EVGN's trailing P/E ratio?
EVGN's trailing P/E is -0.40, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does EVGN next report earnings?
EVGN is next scheduled to report earnings on 2026-08-26, with a consensus EPS estimate of -0.27 USD.